← Back to patent-cliff list
TYK-01054
Tier C — Watch / tradeTYK-01054
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TEAD
Indications (approved)：Solid tumour, 间皮组织肿瘤, Sarcoma, Schwannoma, Oesophageal cancer, Head and neck squamous cell carcinoma, Pancreatic cancer
Regional status
US
Phase I
2024-04-11
EU
-
China
Phase II
2025-12-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TYK-01054?
Approved indications include: Solid tumour, 间皮组织肿瘤, Sarcoma, Schwannoma, Oesophageal cancer, Head and neck squamous cell carcinoma, Pancreatic cancer.
When does the TYK-01054 patent expire?
No public expiry year is available for TYK-01054 yet; this page updates once verified.
How do I get a quote for TYK-01054 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29